- Home
- MRUS vs CYTK Comparison
MRUS vs CYTK Comparison
Compare MRUS & CYTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MRUS
- CYTK
- Stock Information
- Founded
- MRUS 2003
- CYTK 1997
- Country
- MRUS Netherlands
- CYTK United States
- Employees
- MRUS N/A
- CYTK N/A
- Industry
- MRUS Biotechnology: Pharmaceutical Preparations
- CYTK Biotechnology: Pharmaceutical Preparations
- Sector
- MRUS Health Care
- CYTK Health Care
- Exchange
- MRUS Nasdaq
- CYTK Nasdaq
- Market Cap
- MRUS 5.1B
- CYTK 4.6B
- IPO Year
- MRUS 2016
- CYTK 2004
- Fundamental
- Price
- MRUS $68.95
- CYTK $49.29
- Analyst Decision
- MRUS Strong Buy
- CYTK Buy
- Analyst Count
- MRUS 13
- CYTK 15
- Target Price
- MRUS $92.15
- CYTK $75.57
- AVG Volume (30 Days)
- MRUS 629.8K
- CYTK 3.0M
- Earning Date
- MRUS 10-30-2025
- CYTK 11-05-2025
- Dividend Yield
- MRUS N/A
- CYTK N/A
- EPS Growth
- MRUS N/A
- CYTK N/A
- EPS
- MRUS N/A
- CYTK N/A
- Revenue
- MRUS $56,228,000.00
- CYTK $85,738,000.00
- Revenue This Year
- MRUS $48.69
- CYTK $330.96
- Revenue Next Year
- MRUS $3.15
- CYTK $73.41
- P/E Ratio
- MRUS N/A
- CYTK N/A
- Revenue Growth
- MRUS 59.77
- CYTK 2635.74
- 52 Week Low
- MRUS $33.19
- CYTK $29.31
- 52 Week High
- MRUS $70.65
- CYTK $59.39
- Technical
- Relative Strength Index (RSI)
- MRUS 57.97
- CYTK 60.02
- Support Level
- MRUS $66.49
- CYTK $49.22
- Resistance Level
- MRUS $69.63
- CYTK $51.71
- Average True Range (ATR)
- MRUS 2.46
- CYTK 2.69
- MACD
- MRUS -0.07
- CYTK -0.22
- Stochastic Oscillator
- MRUS 78.37
- CYTK 74.05
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.
About CYTK Cytokinetics Incorporated
Cytokinetics Inc is a late-stage biopharmaceutical company focused on discovering, developing and commercializing first-in-class muscle activators and next-in-class muscle inhibitors as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. The company develops treatments for diseases such as amyotrophic lateral sclerosis, heart failure, spinal muscular atrophy, and chronic obstructive pulmonary diseases. The treatment is based on small molecules specifically engineered to increase muscle function and contractility. The company is developing muscle-directed investigational medicines that may potentially improve the health span of people with devastating cardiovascular and neuromuscular diseases of impaired muscle function.